SAFETY, EFFICACY, AND EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF RELAPSED OR REFRACTORY CD30+ HODGKIN LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.66104/hkgjcw62Palabras clave:
Hodgkin lymphoma, Brentuximab Vedotin, treatment, systematic reviewResumen
This systematic review reassessed the efficacy, safety, and impact on quality of life of Brentuximab Vedotin (BV) in treating relapsed/refractory (R/R) CD30+ Hodgkin lymphoma after autologous stem cell transplantation (ASCT). The review followed the Cochrane Handbook for Systematic Reviews of Interventions, with results reported according to PRISMA guidelines. The initial search was conducted on December 11, 2024. A total of 2291 studies were identified; eight met the eligibility criteria, including one phase 3 randomized controlled trial (RCT) and seven retrospective observational studies. In total, 1628 patients received BV after relapse or progression post ASCT, while 924 received comparator therapies such as chemotherapy, checkpoint inhibitors, anthracyclines, gemcitabine, pembrolizumab, and radiotherapy. Risk of bias assessments using RoB 2.0 and ROBINS-I indicated variable risk, ranging from some concerns to moderate or serious. The certainty of evidence, assessed using the GRADE approach, ranged from moderate to low, resulting in a weak recommendation. Overall, BV either as monotherapy or combined with other treatments, showed promising potential for inducing disease remission in patients with R/R CD30+ Hodgkin lymphoma after ASCT. However, limitations in the current evidence underscore the need for more robust, high-quality studies to confirm and strengthen these findings.
Descargas
Referencias
1. Mantey NRC, Muller EV, Montenegro MLV, Mantey JMC. Temporal trend of mortality due to Hodgkin and non-Hodgkin lymphoma in Brazil, 2001 to 2018. Saude Desenv Hum. 2023;11(1):1-12. https//doi.org/10.18316/sdh.v11i1.8929.
2. Moreira GS, Fernandes CLA, Andrade IKB, Leite RP, Oliveira MER, et al. Clinical and epidemiological profile of Hodgkin lymphoma cases in Brazil and their association with systemic lupus erythematosus. Research, Society and Development. 2024;13(4). https//doi.org/10.33448/rsd-v13i4.45391.
3. Araújo JAF, Firmino TAB, Santana FAA, Claudino KCS, Aoyama EA. Hodgkin lymphoma: the importance of early diagnosis by the nursing team. Brazilian Journal of Health Review. 2019;2(1):171–176. Available from: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/878/759.
4. Higgins J, Thomas J, et al. Cochrane handbook for systematic reviews of interventions. Cochrane. 2024;6,5. Available from: https://www.training.cochrane.org/handbook.
5. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Medicine. 2021;18(3). https//doi.org/10.1371/journal.pmed.1003583.
6. RAYYAN – Intelligent Systematic Review. Available from: https://www.rayyan.ai.
7. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https//doi.org/10.1136/bmj.l4898.
8. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355. https//doi.org/10.1136/bmj.i4919.
9. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336 (7650):924–926. https//doi.org/10.1136/bmj.39489.470347.AD.
10. Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncology. 2021;22(4):512–524. https//doi.org/ 10.1016/S1470-2045(21)00005-X.
11. Martínez C, de Haro ME, Romero S, Gutiérrez A, Domingo-Domènech E, et al. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma. Annals of Hematology. 2023;102(2):429–437. https//doi.org/10.1007/s00277-022-05011-6.
12. Desai SH, Spinner MA, Evens AM, Sykorova A, Bachanova V, et al. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. Blood Advances. 2023;7(23):7295–7303. https//doi.org/10.1182/bloodadvances.2023011205.
13. Tun AM, Wang Y, Matin A, Inwards DJ, Habermann TM, et al. Outcomes of patients with classic Hodgkin lymphoma who relapsed after autologous stem cell transplant. HemaSphere. 2023;7(4):869. https//doi.org/10.1097/HS9.0000000000000869.
14. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Advances. 2020;4(1):47–54. https//doi.org/10.1182/bloodadvances.2019000981.
15. Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, et al. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: a nationwide analysis. Hematology Oncology. 2018;36(4):645–650. https//doi.org/10.1002/hon.2541.
16. Zagadailov EA, Corman S, Chirikov V, Johnson C, Macahilig C, et al. Real-world effectiveness of brentuximab vedotin versus physician’s choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leukemia & Lymphoma. 2018;59(6):1413-1419. https//doi.org/10.1080/10428194.2017.1382698.
17. Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, et al. Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. American Journal of Hematology. 2017;92(9):879–884. https//doi.org/ 10.1002/ajh.24792.
18. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18)2183-9. https//doi.org/10.1200/JCO.2011.38.0410.
19. Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, et al. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013;98(8):1232-6. https//doi.org/ 10.3324/haematol.2012.083048.
20. Perrot A, Monjanel H, Bouabdallah R, Quittet P, Sarkozy C, et al. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016;101:466-73.
21. Massaro F, Pavone V, Stefani PM, Botto B, Pulsoni A, et al. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: a Fondazione Italiana Linfomi real-life experience. Hematology Oncology. 2022;40(1):31–39. https//doi.org/10.1002/hon.2939.
22. Moretti M, Liberati AM, Rigacci L, Puccini B, Pulsoni A, et al. Brentuximab vedotin and bendamustine produce long-term clinical benefit in patients with relapsed or refractory classical Hodgkin lymphoma: a multicenter real-life experience. Clinical Lymphoma Myeloma and Leukemia. 2022;22(3):198–204. https// doi.org/10.1016/j.clml.2021.09.018.
23. NATIONAL COMMISSION FOR THE INCORPORATION OF HEALTH TECHNOLOGIES (CONITEC). Brentuximab vedotin for the treatment of adult patients with refractory or relapsed CD30+ Hodgkin lymphoma after autologous hematopoietic stem cell transplantation. Ministry of Health, 2019. Available from: http://conitec.gov.br/images/Relatorios/2019/Relatorio_Brentuximabe_LinfomaHodgkin.pdf. Accessed on: July 19, 2022.
24. Uncu Ulu B, Dal MS, Yönal Hindilerden İ, Akay OM, Mehtap Ö, et al. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Journal of Chemotherapy. 2022;34(3):190–198. https//doi.org/10.1080/1120009X.2021.1976912.
25. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, et al. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica. 2023;108(11):3025–3032. https//doi.org/10.3324/haematol.2023.282780.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Joyce da Silva Guimarães, Paulo Henrique Gouveia, Layssa Andrade Oliveira, Fernanda Stumpf Tonin, Roberto Pontarolo, Yara Maria da Silva Pires, Astrid Wiens
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
